Earnings ·
Reports Q3 revenue of $410.1M and net income of $42.3M ahead of pending Boston Scientific acquisition
PENPenumbra Inc
Penumbra reported third-quarter revenue of $410.1 million, up 15.6% year-over-year, driven by a 18.1% increase in global thrombectomy sales to $279.2 million and a 10.8% rise in embolization and access revenue to $131.0 million. Net income was $42.3 million, or $1.07 per diluted share, compared to $45.9 million in the prior-year period. The company cited $7.1 million in acquisition-related expenses associated with its pending merger with Boston Scientific Corporation as a factor in operating costs. Penumbra will not provide full-year 2026 guidance or host an earnings call due to the pending transaction. Penumbra is a medical device company specializing in thrombectomy technologies for treating ischemic stroke and venous thromboembolism.